Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. SCYX
SCYX logo

SCYX News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

SCYX News

SCYNEXIS Announces 1-for-8 Reverse Stock Split

May 22 2026seekingalpha

SCYNEXIS Announces Reverse Stock Split Plan

May 22 2026Newsfilter

SCYNEXIS Completes Acquisition of SCY-770 for ADPKD Treatment

May 11 2026Newsfilter

SCYNEXIS Approves Inducement Equity Awards for New VP

May 07 2026Newsfilter

U.S. March Manufacturing PMI Slightly Rises

Apr 01 2026seekingalpha

SCYNEXIS Secures $40M in Securities Purchase Agreement

Mar 31 2026seekingalpha

Scynexis Acquires Kidney Disease Treatment, Shares Surge

Mar 31 2026stocktwits

Poxel SA Sells Drug Candidate PXL770 to Scynexis for Up to $196 Million

Mar 31 2026NASDAQ.COM

SCYX Events

06/30 08:30
Scynexis Initiates Phase 1 Study of SCY-770
Scynexis announced initiation of a Phase 1 study of SCY-770, an AMP-activated protein kinase activator. The study will characterize the food-effect and define the pharmacokinetics of two dosing regimens for SCY-770 to support dose selection for the Phase 2 study in patients with Autosomal Dominant Polycystic Kidney Disease, on track for Q4.
05/29 20:00
Scynexis Trading Halted, News Pending
Scynexis trading halted, news pending
05/11 16:30
Company Cash and Investments Total $72.4 Million
Cash, cash equivalents and investments totaled $72.4M on March 31, compared to $56.3M on December 31, 2025. The balance at March 31 includes approximately $24M of the gross proceeds of $40M from the private placement that closed on April 1 with certain new and existing institutional and accredited investors. The March 31 balance plus the approximately $16M in gross proceeds received on April 1 extends the company's cash runway to mid-2029.

SCYX Monitor News

SCYNEXIS Inc stock rises amid market gains

Mar 31 2026

SCYX Earnings Analysis

No Data

No Data

People Also Watch